866-997-4948(US-Canada Toll Free)

Myelodysplastic Syndrome - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Oncology

No. of Pages : 438 Pages

Myelodysplastic Syndrome - Pipeline Review, H1 2014

Summary

Global Markets Directs, Myelodysplastic Syndrome - Pipeline Review, H1 2014, provides an overview of the Myelodysplastic Syndromes therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myelodysplastic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Myelodysplastic Syndrome Overview 11
Therapeutics Development 12
Pipeline Products for Myelodysplastic Syndrome - Overview 12
Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis 13
Myelodysplastic Syndrome - Therapeutics under Development by Companies 14
Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 20
Myelodysplastic Syndrome - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Myelodysplastic Syndrome - Products under Development by Companies 26
Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 28
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 29
Bristol-Myers Squibb Company 29
Boehringer Ingelheim GmbH 30
F. Hoffmann-La Roche Ltd. 31
Amgen Inc. 32
Eli Lilly and Company 33
Athersys, Inc. 34
GlaxoSmithKline plc 35
Daiichi Sankyo Company, Limited 36
medac GmbH 37
Merck & Co., Inc. 38
Dainippon Sumitomo Pharma Co., Ltd. 39
Gamida Cell Ltd. 40
Bio-Path Holdings, Inc. 41
Millennium Pharmaceuticals, Inc. 42
Novartis AG 43
BioMarin Pharmaceutical Inc. 44
Eisai Co., Ltd. 45
Pfizer Inc. 46
Sunesis Pharmaceuticals, Inc. 47
Astex Pharmaceuticals, Inc. 48
Teva Pharmaceutical Industries Limited 49
Cyclacel Pharmaceuticals Inc. 50
Celgene Corporation 51
Incyte Corporation 52
4SC AG 53
Celldex Therapeutics, Inc. 54
Lorus Therapeutics Inc. 55
MEI Pharma, Inc. 56
OXiGENE, Inc. 57
Telik, Inc. 58
Array BioPharma Inc. 59
JW Pharmaceutical Corporation 60
Threshold Pharmaceuticals, Inc. 61
Synta Pharmaceuticals Corp. 62
BioAlliance Pharma SA 63
Cellerant Therapeutics, Inc. 64
Fujifilm Corporation 65
Chroma Therapeutics Ltd. 66
Ambit Biosciences Corporation 67
Actinium Pharmaceuticals, Inc. 68
Acceleron Pharma, Inc. 69
BioMAS Ltd. 70
Apogenix GmbH 71
Celator Pharmaceuticals, Inc. 72
Agios Pharmaceuticals, Inc. 73
TetraLogic Pharmaceuticals 74
Stemline Therapeutics, Inc. 75
Cornerstone Pharmaceuticals, Inc. 76
Onconova Therapeutics, Inc. 77
Concert Pharmaceuticals, Inc. 78
Kiadis Pharma B.V. 79
Bellicum Pharmaceuticals, Inc. 80
KaloBios Pharmaceuticals, Inc. 81
EpiZyme, Inc. 82
Targa Therapeutics Corp. 83
Advancell 84
Immune Pharmaceuticals, Inc. 85
Formula Pharmaceuticals, Inc. 86
AbbVie Inc. 87
Myelodysplastic Syndrome - Therapeutics Assessment 88
Assessment by Monotherapy Products 88
Assessment by Combination Products 89
Assessment by Target 90
Assessment by Mechanism of Action 95
Assessment by Route of Administration 100
Assessment by Molecule Type 102
Drug Profiles 105
StemEx - Drug Profile 105
darbepoetin alfa - Drug Profile 107
azacitidine - Drug Profile 109
(cytarabine + daunorubicin) - Drug Profile 112
rigosertib sodium - Drug Profile 114
treosulfan - Drug Profile 117
lenalidomide - Drug Profile 119
vosaroxin - Drug Profile 122
ganetespib - Drug Profile 124
galunisertib - Drug Profile 128
SGI-110 - Drug Profile 130
sotatercept - Drug Profile 132
mocetinostat - Drug Profile 134
panobinostat - Drug Profile 137
tosedostat - Drug Profile 143
CPI-613 - Drug Profile 145
E-7070 - Drug Profile 147
ATIR - Drug Profile 149
dasatinib - Drug Profile 150
pracinostat - Drug Profile 153
omacetaxine mepesuccinate - Drug Profile 155
eltrombopag olamine - Drug Profile 157
ezatiostat hydrochloride - Drug Profile 160
sapacitabine - Drug Profile 162
luspatercept - Drug Profile 164
rigosertib sodium - Drug Profile 165
vorinostat - Drug Profile 168
AS-101 - Drug Profile 171
Iodine I-131 Monoclonal Antibody BC8 + [cyclophosphamide] + [fludarabine phosphate] + [mycophenolate mofetil] + [tacrolimus] + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 173
glasdegib - Drug Profile 174
temozolomide - Drug Profile 176
INCB-24360 - Drug Profile 178
Iomab-B - Drug Profile 180
vismodegib - Drug Profile 182
acadesine - Drug Profile 185
tosedostat - Drug Profile 187
histamine dihydrochloride - Drug Profile 189
MEK-162 - Drug Profile 191
ruxolitinib phosphate - Drug Profile 194
SL-401 - Drug Profile 198
quizartinib - Drug Profile 200
KB-004 - Drug Profile 202
Cytokine-Induced Killer Cells - Drug Profile 204
sodium stibogluconate - Drug Profile 205
birinapant - Drug Profile 206
BPX-501 - Drug Profile 208
WT-4869 - Drug Profile 209
PD-616 - Drug Profile 210
Minor Histocompatibility Antigen - Drug Profile 212
volasertib - Drug Profile 213
pevonedistat hydrochloride - Drug Profile 215
CDX-1401 - Drug Profile 217
PF-05285401 - Drug Profile 219
azacitidine - Drug Profile 222
4SC-202 - Drug Profile 225
OXi-4503 - Drug Profile 227
everolimus - Drug Profile 229
ARRY-614 - Drug Profile 233
ruxolitinib phosphate - Drug Profile 234
TH-302 - Drug Profile 238
rigosertib sodium - Drug Profile 245
APG-101 - Drug Profile 248
HuM-195/rGel - Drug Profile 250
ciclopirox olamine - Drug Profile 251
exatecan mesylate - Drug Profile 252
BP-100-1.01 - Drug Profile 254
ilorasertib - Drug Profile 256
glasdegib - Drug Profile 258
BMN-673 - Drug Profile 260
pembrolizumab - Drug Profile 262
CWP-232291 - Drug Profile 264
AG-221 - Drug Profile 266
FPI-01 - Drug Profile 268
EPZ-5676 - Drug Profile 270
Genetically Modified T Cell - Drug Profile 271
FF-10501 - Drug Profile 272
LOR-253 - Drug Profile 273
MRx-102 - Drug Profile 275
ELP-10 - Drug Profile 277
CTP-221 - Drug Profile 278
FF-10501 - Drug Profile 279
(decitabine + E-7727) - Drug Profile 280
AG-120 - Drug Profile 281
Cancer Stem Cell Antibody Program - Drug Profile 283
rigosertib sodium - Drug Profile 284
Myelodysplastic Syndrome - Recent Pipeline Updates 287
Myelodysplastic Syndrome - Dormant Projects 418
Myelodysplastic Syndrome - Discontinued Products 419
Myelodysplastic Syndrome - Product Development Milestones 420
Featured News & Press Releases 420
Appendix 431
Methodology 431
Coverage 431
Secondary Research 431
Primary Research 431
Expert Panel Validation 431
Contact Us 432
Disclaimer 432

List of Table

List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H1 2014 18
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Development by Companies, H1 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Development, H1 2014 30
Comparative Analysis by Unknown Stage Development, H1 2014 31
Products under Development by Companies, H1 2014 32
Products under Investigation by Universities/Institutes, H1 2014 34
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2014 35
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H1 2014 36
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 37
Myelodysplastic Syndrome - Pipeline by Amgen Inc., H1 2014 38
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H1 2014 39
Myelodysplastic Syndrome - Pipeline by Athersys, Inc., H1 2014 40
Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline plc, H1 2014 41
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 42
Myelodysplastic Syndrome - Pipeline by medac GmbH, H1 2014 43
Myelodysplastic Syndrome - Pipeline by Merck & Co., Inc., H1 2014 44
Myelodysplastic Syndrome - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 45
Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd., H1 2014 46
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings, Inc., H1 2014 47
Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 48
Myelodysplastic Syndrome - Pipeline by Novartis AG, H1 2014 49
Myelodysplastic Syndrome - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 50
Myelodysplastic Syndrome - Pipeline by Eisai Co., Ltd., H1 2014 51
Myelodysplastic Syndrome - Pipeline by Pfizer Inc., H1 2014 52
Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2014 53
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 54
Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 55
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 56
Myelodysplastic Syndrome - Pipeline by Celgene Corporation, H1 2014 57
Myelodysplastic Syndrome - Pipeline by Incyte Corporation, H1 2014 58
Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2014 59
Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics, Inc., H1 2014 60
Myelodysplastic Syndrome - Pipeline by Lorus Therapeutics Inc., H1 2014 61
Myelodysplastic Syndrome - Pipeline by MEI Pharma, Inc., H1 2014 62
Myelodysplastic Syndrome - Pipeline by OXiGENE, Inc., H1 2014 63
Myelodysplastic Syndrome - Pipeline by Telik, Inc., H1 2014 64
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc., H1 2014 65
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corporation, H1 2014 66
Myelodysplastic Syndrome - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 67
Myelodysplastic Syndrome - Pipeline by Synta Pharmaceuticals Corp., H1 2014 68
Myelodysplastic Syndrome - Pipeline by BioAlliance Pharma SA, H1 2014 69
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics, Inc., H1 2014 70
Myelodysplastic Syndrome - Pipeline by Fujifilm Corporation, H1 2014 71
Myelodysplastic Syndrome - Pipeline by Chroma Therapeutics Ltd., H1 2014 72
Myelodysplastic Syndrome - Pipeline by Ambit Biosciences Corporation., H1 2014 73
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 74
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma, Inc., H1 2014 75
Myelodysplastic Syndrome - Pipeline by BioMAS Ltd., H1 2014 76
Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H1 2014 77
Myelodysplastic Syndrome - Pipeline by Celator Pharmaceuticals, Inc., H1 2014 78
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals, Inc., H1 2014 79
Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H1 2014 80
Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics, Inc., H1 2014 81
Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2014 82
Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics, Inc., H1 2014 83
Myelodysplastic Syndrome - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 84
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma B.V., H1 2014 85
Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 86
Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 87
Myelodysplastic Syndrome - Pipeline by EpiZyme, Inc., H1 2014 88
Myelodysplastic Syndrome - Pipeline by Targa Therapeutics Corp., H1 2014 89
Myelodysplastic Syndrome - Pipeline by Advancell, H1 2014 90
Myelodysplastic Syndrome - Pipeline by Advancell, H1 2014 91
Myelodysplastic Syndrome - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 92
Myelodysplastic Syndrome - Pipeline by AbbVie Inc., H1 2014 93
Assessment by Monotherapy Products, H1 2014 94
Assessment by Combination Products, H1 2014 95
Number of Products by Stage and Target, H1 2014 98
Number of Products by Stage and Mechanism of Action, H1 2014 103
Number of Products by Stage and Route of Administration, H1 2014 107
Number of Products by Stage and Molecule Type, H1 2014 110
Myelodysplastic Syndrome Therapeutics - Recent Pipeline Updates, H1 2014 293
Myelodysplastic Syndrome - Dormant Projects, H1 2014 424
Myelodysplastic Syndrome - Discontinued Products, H1 2014 425

List of Chart

List of Figures
Number of Products under Development for Myelodysplastic Syndrome, H1 2014 18
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Products, H1 2014 30
Assessment by Monotherapy Products, H1 2014 94
Assessment by Combination Products, H1 2014 95
Number of Products by Top 10 Target, H1 2014 96
Number of Products by Stage and Top 10 Target, H1 2014 97
Number of Products by Top 10 Mechanism of Action, H1 2014 101
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 102
Number of Products by Top 10 Route of Administration, H1 2014 106
Number of Products by Stage and Top 10 Route of Administration, H1 2014 107
Number of Products by Top 10 Molecule Type, H1 2014 108
Number of Products by Stage and Top 10 Molecule Type, H1 2014 109

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *